Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN Smallpox Vaccine Safety and Immunogenicity in HIV-Infected Subjects
NCT02038881Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Apr 2014
- Primary completion
- May 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of JYNNEOS in smallpox (3 arms), sponsored by Bavarian Nordic. Primary endpoint: Serious Adverse Events at 75 weeks. Started Apr 2014; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT02038881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038881.